Bone Biopsy Confirmed Imatinib-Induced Bone Marrow Necrosis in Patient with Gastrointestinal Tumor: A Case Report

Imatinib mesylate is an effective, small-molecule, selective tyrosine kinase inhibitor, which inhibits BCR-ABL in patients with chronic myeloid leukemia, c-kit gastrointestinal tumor (GIST), and platelet-derived growth factors hypereosinophilic syndrome. Above all, bone marrow necrosis a rare complication of imatinib usage. If newly developed increased opacity lesions are seen metastatic GIST, it usual to consider those as metastasis. Also, true that making differential diagnosis between change (bone necrosis) disease progression metastasis) both clinically radiologically difficult. Because may alter treatment options according early distinguish metastasis related-bone necrosis, biopsy recommended. Here, we report case confirmed due imatinib, even though investigations such magnetic resonance imaging, whole-body scan indicated more favor the lesion.